ā˜°

Deborah R Kaye, MD, MS - Publications

Affiliations: 
2009-2010 National Cancer Institute, Rockville, MD, United States 
 2018- Urology Duke University Medical School, Durham, NC, United States 
Tree Info Similar researchers PubMed Report error

39 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Kaye DR, Khilfeh I, Muser E, Morrison L, Kinkead F, Lefebvre P, Pilon D, George D. Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States. Journal of Medical Economics. 27: 381-391. PMID 38420699 DOI: 10.1080/13696998.2024.2323901  0.389
2024 Kaye DR, Khilfeh I, Muser E, Morrison L, Kinkead F, Urosevic A, Lefebvre P, Pilon D, George DJ. Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation. Journal of Medical Economics. 1-39. PMID 38204397 DOI: 10.1080/13696998.2024.2303890  0.321
2023 Moses KA, Sprenkle PC, Bahler C, Box G, Carlsson SV, Catalona WJ, Dahl DM, Dall'Era M, Davis JW, Drake BF, Epstein JI, Etzioni RB, Farrington TA, Garraway IP, Jarrard D, ... ... Kaye D, et al. NCCN GuidelinesĀ® Insights: Prostate Cancer Early Detection, Version 1.2023. Journal of the National Comprehensive Cancer Network : Jnccn. 21: 236-246. PMID 36898362 DOI: 10.6004/jnccn.2023.0014  0.349
2023 Kaye DR, Lee HJ, Gordee A, George DJ, Ubel PA, Scales CD, Bundorf MK. Medication Payments by Insurers and Patients for the Treatment of Metastatic Castrate-Resistant Prostate Cancer. Jco Oncology Practice. OP2200645. PMID 36689695 DOI: 10.1200/OP.22.00645  0.32
2022 Wilcox Vanden Berg RN, George AK, Kaye DR. Should Transperineal Prostate Biopsy Be the Standard of Care? Current Urology Reports. PMID 36512186 DOI: 10.1007/s11934-022-01139-0  0.328
2021 Sessine MS, Das S, Park B, Salami SS, Kaffenberger SD, Kasputis A, Solorzano M, Luke M, Vince RA, Kaye DR, Borza T, Stoffel EM, Cobain E, Merajver SD, Jacobs MF, et al. Initial Findings from a High Genetic Risk Prostate Cancer Clinic. Urology. PMID 34280438 DOI: 10.1016/j.urology.2021.05.078  0.36
2020 Ginsburg KB, Jacobs JC, Qi J, Kaye DR, Eggly SS, Linsell SM, Auffenberg GB, George AK, Montie JE, Cher ML. Impact of Early Confirmatory Tests on Upgrading and Conversion to Treatment in Prostate Cancer Patients on Active Surveillance. Urology. PMID 32946908 DOI: 10.1016/J.Urology.2020.07.067  0.465
2019 Ginsburg KB, Arcot R, Qi J, Linsell SM, Kaye DR, George AK, Cher ML. Confirmatory MRI With or Without Biopsy Impacts Decision-Making in Newly Diagnosed Favorable Risk Prostate Cancer. The Journal of Urology. PMID 30694939 DOI: 10.1097/Ju.0000000000000059  0.369
2019 Kaye D, Zhu Z, Ellimoottil C, Dupree J, Miller D, Herrel L. Pd58-07 Health System Characteristics And The Quality Of Urological Cancer Care At The End Of Life The Journal of Urology. 201. DOI: 10.1097/01.Ju.0000557175.12474.58  0.351
2019 Arcot R, Ginsburg K, Qi J, Linsell S, Kaye D, George A, Cher M. Pd55-07 Mri With Or Without Biopsy As A Confirmatory Test In Newly Diagnosed Favorable Risk Prostate Cancer Aids In Decision-Making The Journal of Urology. 201. DOI: 10.1097/01.Ju.0000557074.87014.B1  0.429
2019 Herrel L, Zhu Z, Kaye D, Ellimoottil C, Dupree J, Hollenbeck B, Miller D. Mp44-08 Quality Of Urological Cancer Care At The End Of Life For Dual Eligible Beneficiaries And The Impact Of Delivery System Integration The Journal of Urology. 201. DOI: 10.1097/01.Ju.0000556251.02636.8E  0.335
2018 Hu JC, Tosoian JJ, Qi J, Kaye D, Johnson A, Linsell S, Montie JE, Ghani KR, Miller DC, Wojno K, Burks FN, Spratt DE, Morgan TM. Clinical Utility of Gene Expression Classifiers in Men With Newly Diagnosed Prostate Cancer. Jco Precision Oncology. 2. PMID 32832833 DOI: 10.1200/po.18.00163  0.335
2018 Kaye DR, Dunn RL, Li J, Herrel LA, Dupree JM, Miller DC, Ellimoottil C. Variation in Physician-Specific Episode Payments for Major Cancer Surgery and Implications for the Merit-Based Incentive Program. The Journal of Surgical Research. 236: 30-36. PMID 30694769 DOI: 10.1016/J.Jss.2018.09.073  0.354
2018 Kaye DR, Qi J, Morgan TM, Linsell S, Ginsburg KB, Lane BR, Montie JE, Cher ML, Miller DC. Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance. Bju International. PMID 30248225 DOI: 10.1111/Bju.14554  0.42
2018 Kaye DR, Ye Z, Li J, Herrel LA, Dupree JM, Ellimootil C, Miller DC. The stability of physician-specific episode costs for urological cancer surgery: Implications for Urologists under the Merit-Based Incentive Program (MIPS). Urology. PMID 30125647 DOI: 10.1016/J.Urology.2018.04.051  0.33
2018 Kaye DR, Qi J, Morgan TM, Linsell S, Lane BR, Montie JE, Cher ML, Miller DC. Association between Early Confirmatory Testing and the Adoption of Active Surveillance for Men with Favorable-Risk Prostate Cancer. Urology. PMID 29792972 DOI: 10.1016/J.Urology.2018.04.038  0.408
2018 Kaye DR, Min HS, Herrel LA, Dupree JM, Ellimoottil C, Miller DC. Costs of Cancer Care Across the Disease Continuum. The Oncologist. PMID 29567821 DOI: 10.1634/Theoncologist.2017-0481  0.392
2018 Kaye DR, Min HS, Norton EC, Ye Z, Li J, Dupree JM, Ellimoottil C, Miller DC, Herrel LA. System-Level Health-Care Integration and the Costs of Cancer Care Across the Disease Continuum. Journal of Oncology Practice. JOP2017027730. PMID 29443647 DOI: 10.1200/Jop.2017.027730  0.327
2018 Kaye D, Qi J, Morgan T, Linsell S, Lane B, Montie J, Miller D, Cher M, Urological Surgery Improvement Coll ftM. MP17-02 THE IMPACT OF CONFIRMATORY TESTING ON THE ADOPTION OF ACTIVE SURVEILLANCE FOR MEN WITH FAVORABLE-RISK PROSTATE CANCER Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.557  0.454
2018 Ginsburg K, Jacobs J, Kaye D, Qi J, Cher M. Mp12-10 Rates And Variation In Use Of Mri, Genomics, And Prostate Biopsy As Confirmatory Tests In A Large Active Surveillance Cohort The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.397  0.363
2018 Hu J, Spratt D, Tosoian J, Qi J, Kaye D, Johnson A, Linsell S, Montie J, Ghani K, Miller D, Wojno K, Burks F, Morgan T. Pd56-08 Molecular Classifier Testing For Newly Diagnosed Localized Prostate Cancer In The State Of Michigan The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.2640  0.439
2018 Kaye D, Min HS, Herrel L, Dupree J, Ellimootil C, Miller D. Mp76-05 Costs Of Urologic Cancer Care Across The Disease Continuum The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.2573  0.372
2018 Herrel L, Kaye D, Min A, Ellimoottil C, Dupree JM, Miller D. Mp76-04 Accountable Care Organizations And The Cost And Quality Of Urological Cancer Care At The End Of Life The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.2572  0.337
2018 Kaye D, Ye Z, Herrel L, Li J, Dupree J, Ellimootil C, Miller D. Mp76-01 Variation In Physician-Specific Episode Payments For Major Urologic Cancer Surgery: Implications For Mips The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.2569  0.382
2018 Kaye D, Ye Z, Herrel L, Li J, Dupree J, Miller D, Ellimootil C. Mp02-02 The Stability Of Physician-Spending For Urological Cancer Surgery The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.128  0.366
2017 Li J, Ye Z, Dupree JM, Hollenbeck BK, Min HS, Kaye D, Herrel LA, Miller DC, Ellimoottil C. Association of Delivery System Integration and Outcomes for Major Cancer Surgery. Annals of Surgical Oncology. PMID 29285642 DOI: 10.1245/S10434-017-6312-6  0.346
2017 Ellimoottil C, Li J, Ye Z, Dupree JM, Min HS, Kaye D, Herrel LA, Miller DC. Episode-Based Payment Variation for Urological Cancer Surgery. Urology. PMID 29051001 DOI: 10.1016/J.Urology.2017.08.053  0.373
2017 Kaye DR, Richardson CR, Ye Z, Herrel LA, Ellimoottil C, Miller DC. Association Between Patient Satisfaction and Short-Term Outcomes After Major Cancer Surgery. Annals of Surgical Oncology. PMID 28819930 DOI: 10.1245/S10434-017-6049-2  0.358
2017 Kaye DR, Norton EC, Ellimoottil C, Ye Z, Dupree JM, Herrel LA, Miller DC. Understanding the relationship between the Centers for Medicare and Medicaid Services' Hospital Compare star rating, surgical case volume, and short-term outcomes after major cancer surgery. Cancer. PMID 28665483 DOI: 10.1002/Cncr.30866  0.348
2017 Kaye DR, Ellimootil C, Dupree JM, Ye Z, Herrel LA, Min HS, Norton EC, Miller DC. Pd14-02 Centers For Medicare And Medicaid Services' (Cms) Hospital Compare Star Rankings And Short-Term Outcomes After Major Urological Cancer Surgery The Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.703  0.342
2017 Li J, Ye Z, Min HS, Kaye D, Herrel L, Dupree J, Miller D, Ellimoottil C. Pd14-01 Variation In 90-Day Episode Payments For Urological Cancer Surgery: Implications For Bundled Payment Programs The Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.702  0.352
2017 Kaye DR, Min HS, Ellimootil C, Ye Z, Li J, Herrel LA, Dupree JM, Miller DC. Pd32-02 Understanding Pre-Enrollment First Year Costs Of Urological Cancer Care For Hospitals That Went On To Participate In Medicare Accountable Care Organizations The Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1393  0.349
2016 Kaye DR, Pinto PA, Cecchi F, Reilly J, Semerjian A, Rabe DC, Gupta G, Choyke PL, Bottaro DP. Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer. Plos One. 11: e0157130. PMID 27300295 DOI: 10.1371/Journal.Pone.0157130  0.672
2016 Chappidi MR, Kates M, Patel HD, Tosoian JJ, Kaye DR, Sopko NA, Lascano D, Liu JJ, McKiernan J, Bivalacqua TJ. Frailty as a marker of adverse outcomes in patients with bladder cancer undergoing radical cystectomy. Urologic Oncology. PMID 26899289 DOI: 10.1016/J.Urolonc.2015.12.010  0.396
2015 Kaye DR, Pinto PA, Cecchi F, Reilly J, Semerjian A, Giubellino A, Gupta G, Choyke PL, Linehan WM, Bottaro DP. MP6-17 PREDICTIVE VALUE OF PLASMA SOLUBLE MET PROTEIN CONCENTRATION IN PATIENTS WITH PROSTATE CANCER Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.264  0.661
2015 Kaye D, DeWeese T, Chalfin H, Trock B, Feng Z, Han M. Mp32-06 Does The Ownership Of Radiation Oncology Services Affect Urologists' Practice Patterns For The Treatment Of Prostate Cancer? The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1402  0.324
2014 Kaye DR, Stoianovici D, Han M. Robotic ultrasound and needle guidance for prostate cancer management: review of the contemporary literature. Current Opinion in Urology. 24: 75-80. PMID 24257431 DOI: 10.1097/Mou.0000000000000011  0.416
2012 Hyndman ME, Kaye D, Field NC, Lawson KA, Smith ND, Steinberg GD, Schoenberg MP, Bivalacqua TJ. The use of regenerative medicine in the management of invasive bladder cancer. Advances in Urology. 2012: 653652. PMID 23019421 DOI: 10.1155/2012/653652  0.32
2012 Kaye DR, Walsh PC, Netto GJ, Gonzalez-Roibon N, Rodriguez R. A 66-year-old man with prostate-specific antigen recurrence and lung mass after radical prostatectomy. Urology. 80: 247-9. PMID 22673543 DOI: 10.1016/J.Urology.2012.03.010  0.408
Show low-probability matches.